FDA Master Protocols for Drug and Biological Product Development Guidance for Industry(Catapult’s regulatory round-up – february 2024)

Étiquettes : BiologicalsFDAGuidanceIndustry

• Article suivant FDA Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile Guidance for Industry and Food and Drug Administration Staff (Catapult’s regulatory round-up – february 2024)
• Article précédent FDA Consultation for draft guidance on Advanced Manufacturing Technologies Designation Program (Catapult’s regulatory round-up – february 2024)

Vous aimerez aussi...

• 0

  FDA Essential Drug Delivery Outputs for Devices Intended to Deliver Drugs and Biological Products (Catapult’s regulatory round-up – July 2024)

  05/11/2024

   par adelage

   par adelage · Published 05/11/2024

• 0

  EU4Health call for tenders: single framework contract for joint clinical assessments and joint scientific consultations on health technology assessment

  12/09/2024

   par lsgilbert

   par lsgilbert · Published 12/09/2024

• 0

  Public consultation on Human Gene Therapy Products incorporating Human Genome Editing Food and Drug Administration (FDA) (Cell and Gene Therapy Catapult – Regulatory Round-up – April 2022)

  03/08/2022

   par adelage

   par adelage · Published 03/08/2022 · Last modified 23/08/2022